S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
Free Trial

ProQR Therapeutics (PRQR) Earnings Date, Estimates & Call Transcripts

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free PRQR Stock Alerts
$1.89
-0.01 (-0.53%)
(As of 03:24 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
May. 21Estimated
Actual EPS
(Mar. 13)
-$0.08
Consensus EPS
(Mar. 13)
-$0.08
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

PRQR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PRQR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

ProQR Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20241($0.12)($0.12)($0.12)

PRQR Earnings Date and Information

ProQR Therapeutics last posted its quarterly earnings results on March 13th, 2024. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). The business earned $3.54 million during the quarter, compared to analysts' expectations of $27.88 million. ProQR Therapeutics has generated ($0.39) earnings per share over the last year (($0.39) diluted earnings per share). Earnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.37) to ($0.42) per share. ProQR Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 21st, 2024 based off prior year's report dates.

ProQR Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/21/2024
Estimated)		------- 
3/13/2024Q4 2023($0.08)($0.08)-($0.08)$27.88 million$3.54 million
11/7/2023Q3 2023($0.06)($0.08)($0.02)($0.08)$8.63 million$1.49 million
8/3/2023Q2 2023($0.12)($0.11)+$0.01($0.11)$2.77 million$1.31 million
5/16/2023Q1 2023($0.12)($0.12)-($0.12)$2.87 million$0.70 million
3/29/2023Q4 2022($0.20)($0.16)+$0.04($0.16)$1.00 million$0.84 million
11/9/2022Q3 2022($0.23)($0.34)($0.11)($0.34)$1.05 million$0.96 million
8/4/2022Q2 2022($0.26)($0.22)+$0.04($0.22)$1.21 million$1.09 million
5/5/2022Q1 2022($0.25)($0.22)+$0.03($0.22)$1.19 million$1.39 million
2/24/2022Q4 2021($0.26)($0.30)($0.04)($0.30)$0.90 million$0.27 million    
11/4/2021Q3 2021($0.21)($0.22)($0.01)($0.26)$0.80 million$1.03 million
8/5/2021Q2 2021($0.21)($0.24)($0.03)($0.29)$0.80 million$0.29 million
5/6/2021Q1 2021($0.24)($0.25)($0.01)($0.30)$2.40 million$0.17 million  

ProQR Therapeutics Earnings - Frequently Asked Questions

When is ProQR Therapeutics's earnings date?

ProQR Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 21st, 2024 based off last year's report dates. Learn more on PRQR's earnings history.

Did ProQR Therapeutics beat their earnings estimates last quarter?

In the previous quarter, ProQR Therapeutics (NASDAQ:PRQR) reported ($0.08) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.08). Learn more on analysts' earnings estimate vs. PRQR's actual earnings.

How much revenue does ProQR Therapeutics generate each year?

ProQR Therapeutics (NASDAQ:PRQR) has a recorded annual revenue of $7.05 million.

How much profit does ProQR Therapeutics generate each year?

ProQR Therapeutics (NASDAQ:PRQR) has a recorded net income of -$30.43 million. PRQR has generated -$0.39 earnings per share over the last four quarters.

What is ProQR Therapeutics's EPS forecast for next year?

ProQR Therapeutics's earnings are expected to decrease from ($0.37) per share to ($0.42) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:PRQR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative